Marsh & McLennan Companies, Inc. (MRSH) Stock Price Today
Key Stats
- $86.15BMarket Cap
- -Volume
- FinancialsSector
- $207.0252W High
- $157.3252W Low
- -Typical Hold Time
- $106.83BEnterprise Value
- 2.19%Div Yield
- -Trading Activity
Track Marsh & McLennan Companies, Inc. (MRSH) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Marsh & McLennan Companies, Inc. has traded between a low of $157.32 and a high of $207.02, highlighting its annual price range. Buy and sell Marsh & McLennan Companies, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Most Recent News
Automattic CEO Matt Mullenweg placed on leave; CFO Mark Davies named interim CEO amid board dispute.
Matt Mullenweg, founder and CEO of Automattic, was placed on a paid leave of absence by the company's board, with CFO Mark Davies appointed as interim CEO. Mullenweg opposed the decision, which was made without giving him time for legal review. The b...
US Treasury tripled bond buybacks but yields rose; Ron Paul warns against trusting Fort Knox gold accounting.
The US Treasury increased its bond buyback ceiling to $6 billion to ease borrowing costs, but 10-year yields still rose to 4.85%. Ron Paul criticized the government's gold accounting at Fort Knox, highlighting the outdated valuation of $42.22 per oun...
Axsome reports strong growth for its CNS drugs AUVELITY, SYMBRAVO, and SUNOSI with new Alzheimer's agitation launch underway.
Axsome Therapeutics, a biopharma company focused on central nervous system (CNS) disorders, reported robust growth for its three commercial products: AUVELITY (for major depressive disorder and Alzheimer's agitation), SYMBRAVO (for migraine), and SUN...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.